Please provide your email address to receive an email when new articles are posted on . Researchers evaluated the risk of adverse outcomes in older patients across categories of eGFR. The database ...
Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Results showed highest risks for CVD for low eGFR and ...
Credit: Shutterstock Accurate assessment of glomerular filtration rate in patients with cancer is crucial to determine drug eligibility and dosing, while balancing the risks for undertreatment and ...
Zipalertinib showed efficacy in NSCLC with EGFR exon 20 insertions, achieving a 31.3% intracranial ORR and a 27.6% systemic ORR. The drug demonstrated a favorable safety profile, with low rates of ...
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace AstraZeneca’s Tagrisso as the new standard of care in first-line ...
The use of semaglutide for non-diabetic obese patients with cardiovascular disease was first reported to be associated with significant benefit in the SELECT trial, where major adverse cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback